Media Kit

Media Kit

Corporate Background

Akoya Biosciences, The Spatial Biology Company®, offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX® system is the only benchtop platform that can image 40+ protein biomarkers across whole tissue sections, at single-cell resolution and is ideally suited for biomarker discovery. The Phenoptics™ platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.

Logos

Standard Akoya Biosciences Logo

Black Akoya Biosciences Logo

White Akoya Biosciences Logo

Stacked Akoya Biosciences Logo

Black, Stacked Akoya Biosciences Logo

White, Stacked Akoya Biosciences Logo

Instruments

CODEX® System with KEYENCE Microscope

CODEX® System

Vectra® Polaris™ Automated Quantitative Pathology Imaging System with Monitor

Vectra® Polaris™ Automated Quantitative Pathology Imaging System

Vectra® 3 Automated Quantitative Pathology Imaging System, 6 Slide

Mantra ™ 2 Quantitative Pathology Workstation

Selected Press Releases

Akoya Biosciences Raises $50 Million in New Financing
Investment funds significant expansion of Akoya | December 5, 2019

Study Shows Spatial Biology Is Essential for Predicting Response to Immuno-Oncology Treatment
Leading immuno-oncology labs publish study in JAMA Oncology | July 18, 2019

Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer
Akoya Biosciences’ acquisition of PerkinElmer’s Phenoptics portfolio | October 31, 2018

If you have further questions or require additional images please reach us here.
Media Contact for Akoya:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com

Astronomy Meets Pathology: An Interdisciplinary Effort to Discover Predictive Biomarker Signatures

X